Clin Osteol 2010; 15(2): 57-60

Risk of osteoporotic fractures in diabetic patients treated with glitazonesReview articles

J. Payer, P. Jackuliak, Z. Killinger

Osteoporosis is a common complication in patients with both types of diabetes mellitus. In type 2 diabetes patients, the important risk factors for osteoporotic fractures include the use of glitazones. As selective agonists of a group of nuclear receptors, the so-called pe­ roxisome proliferator-activated receptor gamma (PPAR-y), glitazones participate in the inhibition of osteoblast differentiation and sti­ mulation of osteoclasts from haematopoietic cells. The effect is clinically manifested by a higher rate of osteoporotic fractures at pre­ dilection sites (the distal lower extremities and upper extremities), especially in the population at risk, i.e. women over 65 years of age. This potentially negative effect should be borne in mind when long-term therapy with glitazones is indicated in patients at risk of os­ teoporosis.

Keywords: glitazones, PPAR-gamma, osteoporosis, fractures

Published: December 11, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Payer J, Jackuliak P, Killinger Z. Risk of osteoporotic fractures in diabetic patients treated with glitazones. Osteologický bulletin. 2010;15(2):57-60.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Blahoš J. Osteoporóza. Praha, Galén, 1995; p 172.
    2. Mokáň M. Epidemiológia diabetes mellitus. In: Mokáň M., Martinka E., Galajda P. et al. Diabetes mellitus a vybranné metabolické ochorenia. Martin, Vyd. P+M, 2008; p 1003.
    3. Ivers RQ, Cumming RG, Mitchell P, Peduto AJ. Diabetes and risk of fracture: The Blue Mountains Eye Study. Diabetes Care 2001;24:1198-1203. Go to original source...
    4. Palička V. Léky ovlivňující kostní metabolizmus diabetiků. Vnitř Lék 2009;55:368-370.
    5. Schwartz AV, Sellmeyer DE. Women, type 2 diabetes, and fracture risk. Curr Diab Rep 2004;4:364-369, Marcus R, Feldman D, Nelson D, Rosen C. Osteoporosis 3rd Edition. Elsevier 2008. Go to original source...
    6. Brown SA, Sharpless JL. Osteoporosis: An Under-appreciated Complication of Diabetes. Clinical Diabetes 2004;22:10-19. Go to original source...
    7. Rovenský J, Payer J, Calgue RB. Dictionary of Rheumatology. Wien, Springer­ Verlag 2009; p 230. Go to original source...
    8. Payer J, Rovenský J, Killinger Z. Lexikón osteoporózy. Bratislava, SAP - Slovak Academic Press, s.r.o., 2007; p 75.
    9. Ochodnický M. Vybrané metabolické ochorenia. In: Mokáň M., Martinka E., Galajda P. et al. Diabetes mellitus a vybranné metabolické ochorenia. Martin, Vyd. P+M, 2008; p 1003.
    10. Greenfield JR. Chischolm DJ. Thiazolidinediones - mechanism of action. Austr Prescr 2004;27:67-70. Go to original source...
    11. Maclsaac RJ. Jerums G. Clinical indications for thiazolidinediones. Austr Prescr 2004; 27:70-74. Go to original source...
    12. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-1018. Go to original source...
    13. Uličiansky V. Algoritmus liečby diabetes mellitus 2. typu. Prešov, Diabetol s.r.o, 2009; p 285.
    14. Parulkar AA Pendergrass ML. Granda-Ayala R. Lee TR. Fonseca VA Nonhypoglycemic effects ofThiazolidinediones. Ann Intern Med 2001;134:61-71. Go to original source...
    15. Schoonjans K, Auwerx J. Thiazolidinediones: an update. Lancet 2000;355: 1008-1010. Go to original source...
    16. Grey A Skeletal consequences of thiazolidinedione therapy. Osteoporosis Int 2008; 19:129-137.
    17. Wan Y, Chong LW, Evans RM. PPAR-gamma regulates osteoclastogenesis in mi­ ce. Nat Med 2007;13:1496-1503. Go to original source...
    18. Rosen CJ, Bouxsein ML. Mechanism of disease: is osteoporosis the obesity of bo­ ne? Natur Clinical Practice Rheumatology 2006;2:35-43. Go to original source...
    19. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, met­ formin or glyburide monotherapy. New Engl J Med 2006;355:2427-2443. Go to original source...
    20. Kahn SE, Zinman B, Lachin JM et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008;31:845-851. Go to original source...
    21. Holmberg AH, Nilsson J-Á, Ákesson K. The association between hyperglycemia and fracture risk in middle age. A prospective population-based study of 22.444 men and 10.902 women. J Clin Endocrinol Metab 2008;93:815-822. Go to original source...
    22. Meier C, Kraenzlin ME, Bodmer M et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008;168:820-825. Go to original source...
    23. Habib ZA, Havstad SL, Wells K et al. Thiazolidinedione Use and the Longitudinal Risk of Fractures in Patients with Type 2 Diabetes Mellitus. J Clin Endcorinol Metab 2010; 95:592-600. Go to original source...
    24. Hsiao F-Y, Mullins CD. The association between thiazolidinediones and hospita­ lisation for fracture in type 2 diabetic patients: a Taiwanese population-based ne­ sted case-control study. Diabetologia 2010;53:489-496. Go to original source...
    25. Yaturu S, Bryant B, Jain SK. Thiazolidinediones treatment decrease bone mineral density in type 2 diabetic men. Diabetes Care 2007; 30: 1574-1576. Go to original source...
    26. Sanders KM, Seeman E, Ugoni AM et al. Age- and gender-specific rate of frac­ tures in Australia: a population-based study. Osteoporosis Int 1999;10:240-247. Go to original source...
    27. Loke Y, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009;180:32-39. Go to original source...
    28. Maclsaac RJ. Jerums G. Clinical indications for thiazolidinediones. Austr Prescr 2004; 27:70-74. Go to original source...
    29. Delea TZ, Edelsberg JS, Hagiwara M, Oster G, Phillips LS. Use of thiazolidine­ diones and risk of heart failure in people with type 2 diabetes. Diabetes Care 2003;26:2983-2989. Go to original source...
    30. National Collaborating Centre for Chronic Conditions. Type 2 diabetes: national clinical guideline for management in primary and secondary care (update). London 2008: Royal College of Physicians.

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.